Abstract Number: 1672 • ACR Convergence 2024
The Evaluation of SLE Outcome Measures in Telemedicine
Background/Purpose: Telemedicine (TM) has been integral to rheumatology care since the Covid-19 pandemic; evidence suggests high acceptance, satisfaction, and feasibility. However, due to the complexity…Abstract Number: 1952 • ACR Convergence 2024
Interest in Clinical Trial Participation Among People with Lupus: Results from the Research Accelerated by You (RAY) Registry
Background/Purpose: With many treatments under study for SLE, a crisis in recruiting sufficient numbers of qualified patients for clinical trials has emerged. Willingness to consider…Abstract Number: 2400 • ACR Convergence 2024
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: External Validation of the PROMISSE Model Using Multiple Independent Cohorts
Background/Purpose: Nearly 20% of pregnancies in systemic lupus erythematosus (SLE) patients result in an adverse pregnancy outcome (APO); early identification of those at high APO…Abstract Number: 2055 • ACR Convergence 2022
SRI-4 and BICLA: How Well Do They Agree Across Trials of Active Systemic Lupus Erythematosus?
Background/Purpose: The Systemic Lupus Erythematosus Responder Index 4 (SRI-4) and the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) are currently the most…Abstract Number: 1268 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus: A Comparison of Machine Learning Methods
Background/Purpose: Nearly 20% of pregnancies in patients with Systemic lupus erythematosus (SLE) result in an adverse pregnancy outcome (APO); early identification of women with SLE…Abstract Number: 1299 • ACR Convergence 2021
Longitudinal Patterns of Response to Standard of Care Therapy for Lupus Nephritis: Data from the Accelerating Medicines Partnership Lupus Network
Background/Purpose: The Accelerating Medicines Partnership (AMP) Lupus Network was established with the goal of applying novel technologies to the interrogation of blood and tissue samples…Abstract Number: 1420 • ACR Convergence 2021
Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
Background/Purpose: Since the Phase 3 clinical studies of all three COVID-19 vaccines excluded patients on immunosuppressants or immune-modifying drugs within 6 months of enrollment, data…Abstract Number: 1500 • ACR Convergence 2020
Electrocardiographic QT Intervals in Infants Exposed to Hydroxychloroquine Throughout Gestation
Background/Purpose: Based on inhibition of viral replication and limited reports on clinical efficacy, hydroxychloroquine (HCQ) was initially considered as a prophylaxis and treatment of COVID-19. …Abstract Number: 1274 • ACR Convergence 2020
COVID-19 in Patients with Systemic Lupus Erythematosus
Background/Purpose: Patients with systemic lupus erythematosus (SLE) represent a unique population in considering risk for coronavirus disease 2019 (COVID-19) with biologic, genetic, demographic, clinical and…Abstract Number: 1761 • 2019 ACR/ARP Annual Meeting
The Prospective Open Label Preventive Approach to Congenital Heart Block with Hydroxychloroquine (PATCH) Study Demonstrates a Reduction in the Recurrence Rate of Advanced Block
Background/Purpose: Based on encouraging bench to bedside results including experimental evidence supporting Toll-like receptor signaling in the pathogenesis of CHB, a case control study demonstrating…Abstract Number: 2535 • 2019 ACR/ARP Annual Meeting
Identifying Subgroups of SLE Patients with Differential Responses to a BLyS Inhibitor: Application of a Machine Learning Algorithm to Clinical Trial Data
Background/Purpose: Given the heterogeneity of systemic lupus erythematosus (SLE), the effect of any intervention is expected to vary. The ability to identify those most and…Abstract Number: 2866 • 2019 ACR/ARP Annual Meeting
Factors Associated with Cardiac Dysfunction in a Longitudinal Follow-Up of Neonatal Lupus
Background/Purpose: Cardiac manifestations of neonatal lupus (NL) have been associated with significant morbidity and mortality, however there has been minimal information on long-term outcomes of…Abstract Number: 1854 • 2018 ACR/ARHP Annual Meeting
SLE Flares during and after Pregnancy Are Mild and Occur at Similar Rates
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects women of childbearing age. Low disease activity for 6 months prior to conception leads to the best outcomes;…Abstract Number: 2931 • 2018 ACR/ARHP Annual Meeting
Missing Outcomes in SLE Clinical Trials: Impact on Estimating Treatment Effects
Background/Purpose: Missing data due to drop-out and loss to follow-up is a common problem in SLE trials. The usual approaches for handling this issue include…Abstract Number: 1838 • 2017 ACR/ARHP Annual Meeting
Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials
Background/Purpose: The primary endpoint in SLE trials is usually response to therapy at a landmark visit. However, during a trial, patients may alternate between response…
Advanced Search Results
-
Title
---